Endocrinology, Diabetes, & Metabolism
There are many anti-hyperglycemic agents that can be used after Meformin in managing type 2 diabetes. DPP4 inhibitors and SGLT2 inhibitors have become popular choices to be used in this context. This presentation will discuss advantages and disadvantages of these two classes of medications and help participants better identify which patients may be better suited for one agent over the other. It will also review potential side effects of these medications and how to possibly reduce the risk of developing these side effects and managing them should they occur.
Full time faculty Sunnybrook Health Sciences Centre
Assistant Professor University of Toronto
Sunnybrook Health Sciences Centre University of Toronto
Dr. Jeremy Gilbert completed his medical school, internal medicine and endocrinology residency training at the University of Toronto. He is an active staff member in the Divisions of Endocrinology at Sunnybrook Health Sciences Centre and assistant professor at the University of Toronto. He serves as the program director for Endocrinology and Metabolism at the University of Toronto. He acts as the endocrinology lead for the Toronto Central LHIN as part of the Ontario Diabetes Strategy and is the co-author of one chapter in the 2013 CDA Guidelines. He is also a member of the steering committee for the 2018 CDA Guidelines and an associate editor for the Canadian Journal of Diabetes. Dr. Gilbert has great enthusiasm for teaching and completed the Master Teacher program at the University of Toronto. His areas of academic interest are undergraduate, postgraduate and continuing medical education in endocrinology and metabolism.
Thursday, November 23
1:15 PM – 2:15 PM
The asset you are trying to access is locked. Please enter your access key to unlock.